Trial
NCT02933801
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Swiss Cancer Institute
Collaborators
—
Condition
Prostate Cancer Metastatic
Intervention
ODM-201
Why stopped
Decision Board no further financial support after 3 years of follow-up as remaining patients in follow-up phase would not relevantly change the endpoints.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-13